NO984229L - Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft - Google Patents

Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft

Info

Publication number
NO984229L
NO984229L NO984229A NO984229A NO984229L NO 984229 L NO984229 L NO 984229L NO 984229 A NO984229 A NO 984229A NO 984229 A NO984229 A NO 984229A NO 984229 L NO984229 L NO 984229L
Authority
NO
Norway
Prior art keywords
prostate cancer
polypeptides
compounds
methods
immunotherapy
Prior art date
Application number
NO984229A
Other languages
English (en)
Norwegian (no)
Other versions
NO984229D0 (no
Inventor
Steven G Reed
Davin C Dillon
Daniel R Twardzik
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO984229D0 publication Critical patent/NO984229D0/no
Publication of NO984229L publication Critical patent/NO984229L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
NO984229A 1996-03-15 1998-09-14 Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft NO984229L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61674596A 1996-03-15 1996-03-15
US63384096A 1996-04-11 1996-04-11
PCT/US1997/004192 WO1997033909A2 (fr) 1996-03-15 1997-03-14 Composes et methodes d'immunotherapie et d'immunodiagnostic pour le cancer de la prostate

Publications (2)

Publication Number Publication Date
NO984229D0 NO984229D0 (no) 1998-09-14
NO984229L true NO984229L (no) 1998-11-13

Family

ID=27087847

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984229A NO984229L (no) 1996-03-15 1998-09-14 Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft

Country Status (11)

Country Link
US (1) US6034218A (fr)
EP (1) EP0914335A2 (fr)
KR (1) KR19990087802A (fr)
AR (1) AR006250A1 (fr)
AU (1) AU728186B2 (fr)
BR (1) BR9708082A (fr)
CA (1) CA2249742A1 (fr)
CO (1) CO4600637A1 (fr)
NO (1) NO984229L (fr)
NZ (1) NZ331866A (fr)
WO (1) WO1997033909A2 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
PL196260B1 (pl) 1997-02-25 2007-12-31 Corixa Corp Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
WO1999018210A2 (fr) * 1997-10-07 1999-04-15 Corixa Corporation Composes et procedes pour l'immunotherapie et l'immunodiagnostic du cancer de la prostate
WO1999037778A2 (fr) * 1998-01-26 1999-07-29 Genquest, Inc. Compositions et procedes de detection et de traitement du cancer de la prostate
HUP0203035A3 (en) * 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB9828840D0 (en) * 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000073469A2 (fr) * 1999-05-28 2000-12-07 Sugen, Inc. Proteines kinases
CA2340721A1 (fr) * 1999-06-21 2001-01-25 George Tuszynski Angiocidine: recepteur d'adherence des cellules tumorales specifiques cys-ser-val-thr-cys-gly
US20020058292A1 (en) * 2000-12-08 2002-05-16 Dillon Davin C. Ovarian tumor antigen and methods of use therefor
EP1229931A4 (fr) * 1999-10-07 2003-05-28 Corixa Corp Proteines hybrides de mycobacterium tuberculosis
AU1656501A (en) * 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2397741A1 (fr) * 2000-01-14 2001-07-19 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
AU2001259228A1 (en) * 2000-04-26 2001-11-07 The Scripps Research Institute Pancreatic progenitor 1 gene and its uses
AU2001280639A1 (en) * 2000-07-18 2002-01-30 Millennium Pharmaceuticals, Inc. 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
WO2002010338A2 (fr) * 2000-07-31 2002-02-07 Gene Logic, Inc. Expression d'une proteine du type gage/page dans l'hypertrophie benigne de la prostate
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020142327A1 (en) * 2000-11-28 2002-10-03 Gillis Kimberly A. Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2429722A1 (fr) 2000-11-28 2002-06-06 Wyeth Analyse de l'expression des acides nucleiques fkbp et polypeptides utiles dans le diagnostic et le traitement du cancer de la prostate
US7037652B2 (en) 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2439442A1 (fr) * 2001-02-26 2002-09-06 Xianghe Yan Proteines proteases humaines isolees, molecules d'acide nucleique codant des proteines proteases humaines et leurs utilisations
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
AU2002302851A1 (en) 2001-06-21 2003-01-08 Isis Innovations Limited Atopy
JP4491567B2 (ja) * 2001-07-19 2010-06-30 財団法人新産業創造研究機構 ヒト由来のスフィンゴシン・キナーゼ１に結合する新規タンパク質、及び当該タンパク質をコードするポリヌクレオチド
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2814598A1 (fr) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Fusion geniques recurrentes dans le cancer de la prostate
ES2459018T3 (es) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008043107A2 (fr) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Utilisation d'antagonistes des jonctions occlusives pour traiter les affections abdominales inflammatoires
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
JP2010508855A (ja) * 2006-11-08 2010-03-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用
US9962424B2 (en) * 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
CA2692793C (fr) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Rearrangements de genes mipol1 -etv1
EP2604701B1 (fr) 2007-07-06 2015-11-04 The Regents Of The University Of Michigan Fusions de gène récurrentes dans le cancer de la prostate
JP5406187B2 (ja) 2007-08-16 2014-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝プロファイリング法
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
KR20110111474A (ko) 2009-01-09 2011-10-11 더 리젠츠 오브 더 유니버시티 오브 미시간 암에서의 반복적 유전자 융합체
US20100311815A1 (en) * 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
EP2478120B1 (fr) 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Fusions de gène récurrentes dans le cancer de la prostate
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP2640854B1 (fr) 2010-11-19 2018-02-21 The Regents Of The University Of Michigan ARNnc PCAT1 ET UTILISATIONS DE CELUI-CI
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2885640B1 (fr) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prognostic du cancer de la prostate au moyen de biomarqueurs
JP2018504595A (ja) 2015-01-05 2018-02-15 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ 前立腺癌マーカー及びその利用
EP3504348B1 (fr) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Utilisation de signatures génomiques en vue d'une prédiction de la réactivité de patients atteints d'un cancer de la prostate à une radiothérapie postopératoire
WO2018132916A1 (fr) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Sous-typage moléculaire, pronostic et traitement du cancer de la vessie
CA3055925A1 (fr) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Sous-typage du cancer de la prostate pour predire la reponse a une therapie hormonale
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
WO2019028285A2 (fr) 2017-08-04 2019-02-07 Genomedx, Inc. Utilisation d'une expression génique spécifique des cellules immunitaires pour le pronostic du cancer de la prostate et la prédiction de la sensibilité à la radiothérapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009446A1 (fr) * 1989-02-17 1990-08-23 Plant Genetic Systems N.V. Cutinase
DE69334071T2 (de) * 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.

Also Published As

Publication number Publication date
WO1997033909A2 (fr) 1997-09-18
KR19990087802A (ko) 1999-12-27
CO4600637A1 (es) 1998-05-08
NO984229D0 (no) 1998-09-14
AR006250A1 (es) 1999-08-11
AU2329597A (en) 1997-10-01
CA2249742A1 (fr) 1997-09-18
WO1997033909A3 (fr) 1997-12-24
BR9708082A (pt) 1999-07-27
US6034218A (en) 2000-03-07
NZ331866A (en) 2000-05-26
AU728186B2 (en) 2001-01-04
EP0914335A2 (fr) 1999-05-12

Similar Documents

Publication Publication Date Title
NO984229L (no) Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft
EP1630235A3 (fr) Composés pour l'immunodiagnostic du cancer de la prostate et méthodes pour leurs utilisations
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
NO20004631D0 (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
HUP0103758A2 (hu) Neurotróf faktorok
WO2000037643A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation
HUP9800784A2 (hu) Angiosztatin-fragmensek, aggregált angiosztatin és alkalmazásuk
WO1997008314A3 (fr) Facteur de liaison telomerique, son utilisation diagnostique et therapeutique
EP1151140A4 (fr) Nouveau gene specifique a la prostate servant au diagnostic, au pronostic et au traitement du cancer de la prostate
EP1589109A3 (fr) Séquences de Borrelia pathogènes semblables à une pmv
WO2000020587A3 (fr) Antigenes associes au cancer et leurs utilisations
AU1959001A (en) Histone deacetylase-8 proteins, nucleic acids, and methods of use
DK11187D0 (da) Dna-sekvenser der koder for proteiner med husi-type i inhibitorers biologiske aktivitet, biotekniske fremgangsmaader til fremstilling af proteinerne o g farmaceutiske praeparater der indeholder dem
WO1999018210A3 (fr) Composes et procedes pour l'immunotherapie et l'immunodiagnostic du cancer de la prostate
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
NO20022711L (no) Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi
WO2001002561A3 (fr) Nouveaux canaux calciques mammiferes et sondes, lignees cellulaires et procedes correspondants
WO2001051513A3 (fr) Sequences associees a une tumeur ovarienne
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
Kitto et al. Structural studies on Dendrostomum pyroides hemerythrin
Voronin et al. Synthesis of a stable isotopically labeled universal surrogate peptide for use as an internal standard in LC‐MS/MS bioanalysis of human IgG and Fc‐fusion protein drug candidates
ATE418604T1 (de) Gegen das prothrombin-fragment f1+2 gerichtete antikörper, ihre herstellung und verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application